Furthermore, we demonstrated an important role of the succinate-related pathway in tumor development and response to treatment in patients with HNSCC, where high succinate receptor 1 (SUCNR1) together with high succinate dehydrogenase A (SDHA) expression predicts poor locoregional disease-free survival in a sub-group of patients treated with RT or chemoradiotherapy (CRT) [9]. This evidence concerns the gene SUCNR1 and neoplasm.